Olivier Danos - 01 Feb 2025 Form 4 Insider Report for REGENXBIO Inc. (RGNX)

Reporting relationship: Chief Scientific Officer
Issuer ticker: RGNX
Reported as of: 01 Feb 2025
Net transaction value: -$43,998
SEC form: 4
Accepted by SEC: 04 Apr 2025, 17:16:46 UTC
Prior SEC filing: 06 Jan 2025
Source filing: View source filing
Reporting owner signature: /s/ Patrick J. Christmas as attorney-in-fact

Key filing fact

Olivier Danos filed Form 4 for REGENXBIO Inc. (RGNX) on 04 Apr 2025.

Key facts

This page summarizes Olivier Danos's Form 4 filing for REGENXBIO Inc. (RGNX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 04 Apr 2025, 17:16.

Change

Previous filing in this sequence was filed on 06 Jan 2025.
Current net transaction value: -$43,998.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RGNX transaction

Common Stock

Tax liability

Transaction value: $43,998
Shares: -5,452
Change %: -2.4%
Price: $8.07
Shares after: 226,348
Date: 01 Feb 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Olivier Danos is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 1 footnote

Footnote F1

Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on August 1, 2024. The number of shares withheld was determined based on the closing price of the issuer's common stock on February 1, 2025.